
The Company’s two key projects are ArTiMist™, a malaria treatment developed specifically for children with severe malaria and NiCoSorb™, a nicotine replacement therapy. ArTiMist has the potential to save countless young lives throughout third world and underprivileged regions. NiCoSorb, an anti-smoking therapy, is another life-saving treatment which will assist smokers in their efforts to quit the habit. Growth Strategy
Eastland Medical Systems
Eastland Medical Systems is a publicly listed Company on the Australian Securities Exchange (ASX:EMS) that is involved in the commercialisation of low-risk pharmaceutical projects.

Eastland is committed to developing its pharmaceutical business model by expanding its product portfolio with products that demonstrate major cost, functional and effectual advantages over competitors, thereby securing on-going consumer demand.
Announcements News & Media Releases
1.
SUCCESSFUL PLACEMENT (555 KB)
2.
CALVIN ROSS (890 KB)
3.
BOARDROOM INTERVIEW (554 KB)
4.
Consultant Appointment (560 KB)
5.
10/07/06 Response to ASX Query (2696 KB)
6.
10-07-05 Eastland to present at the 2010 Interscience Conference (600 KB)
7.
10-06-11 Event Impact - Industrial Research (529 KB)
8.
10-06-11 ASX Release - Update on HC Berlin Pharna AG and Clinical Trials (609 KB)
9.
10-05-19 ASX Release No 454 Research Report - ArtiMist (755 KB)
10.
10-04-28 New Treatment to Reduce Deaths in Children with Malaria (605 KB)
11.
10-04-28 ArTiMistâ„¢ Study Highly Successfull in Treating Children With Severe Malaria (623 KB)
Broker Research
1.
UPDATE RESEARCH REPORT (431 KB)
2.
10/07/06 Event Impact - Patersons Securities (548 KB)
3.
10-06-11 Event Impact - Industrial Research (529 KB)
4.
10-05-19 ArtiMist - The Next Front-Line Drug for Severe Malaria (585 KB)
5.
10-04-29 Event Impact - Industrial Research (523 KB)
Roll Back Malaria
Malaria in the News


